MYRIAD GENETICS INC (MYGN)

↓ Download CSV

CIK 0000899923 · Nasdaq · In Vitro & In Vivo Diagnostic Substances

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, MYRIAD GENETICS INC reported revenue of $824.50M, down 1.6% from the prior year. The company ran a net loss, with a net margin of -44.4% and a gross margin of 69.9%. It held $706.60M in total assets against $338.60M in total liabilities.

Key ratios (FY2025)

69.9%
Gross margin
-47.0%
Operating margin
-44.4%
Net margin
-99.4%
Return on equity
-1.6%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$824.50M$837.60M$753.20M$678.40M$690.60M$557.10M$851.10M$743.70M$728.70M$740.50M
Cost of Revenue$247.90M$252.20M$236.20M$202.00M
Gross Profit$576.60M$585.40M$517.00M$476.40M
Operating Income-$387.20M-$123.50M-$257.40M-$140.60M-$190.50M-$289.70M$7.60M$121.90M$44.00M$153.40M
Net Income-$365.90M-$127.30M-$263.30M-$112.00M-$27.20M-$223.60M$4.60M$133.30M$17.40M$117.20M
EPS (Diluted)$-3.95$-1.41$-3.18$-1.39$-0.35$-2.99$0.06$1.85$0.25$1.60
Total Assets$706.60M$1.03B$1.15B$1.20B$1.32B$1.42B$1.56B$1.18B$1.21B$880.50M
Total Liabilities$338.60M$326.50M$363.30M$312.90M$352.90M$537.80M$473.80M$209.20M$440.90M$132.40M
Shareholders' Equity$368.00M$701.10M$783.20M$885.80M$967.80M$881.00M$1.09B$966.10M$768.40M$739.60M
Cash & Equivalents$149.60M$102.40M$132.10M$56.90M$257.40M$117.00M$93.20M$110.90M$102.40M$68.50M
Operating Cash Flow$1.80M-$8.70M-$110.90M-$106.30M$18.60M$60.70M$83.70M$115.90M$106.20M$166.30M
Capital Expenditures$45.30M$18.00M$10.20M$8.60M$8.40M$6.10M$5.00M
Shares Outstanding92.60M90.60M82.80M80.60M78.00M74.80M76.00M72.00M68.80M73.40M